Indications
Brinzolamide + Brimonidine Tartrate ophthalmic suspension is a fixed combination of two medicines: a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist. It is used to lower raised intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Brinzolamide is a carbonic anhydrase inhibitor and Brimonidine Tartrate is an alpha 2 adrenergic receptor agonist. Both of these components lower raised intraocular pressure. Raised intraocular pressure is a major risk factor in the development of optic nerve damage and glaucomatous visual field loss.
Brinzolamide works on carbonic anhydrase in the ciliary processes of the eye and reduces the secretion of aqueous humor. It probably does this by slowing the formation of bicarbonate ions, which then reduces sodium and fluid transport. Its peak ocular hypotensive effect comes 2 to 3 hours after the dose.
Fluorophotometric studies in animals and humans suggest that Brimonidine Tartrate acts in two ways, by reducing aqueous humor production and by increasing uveoscleral outflow. Its peak ocular hypotensive effect comes two hours after the dose. The result is a reduction in intraocular pressure (IOP).
Pregnancy & Breastfeeding
Brinzolamide + Brimonidine Tartrate is Pregnancy Category C. Use it during pregnancy only if the likely benefit justifies the possible risk to the fetus.
No one knows whether Brinzolamide + Brimonidine Tartrate passes into human milk after it is put in the eye. Many drugs do pass into breast milk, and this one could cause serious adverse reactions in a nursing infant. So a decision has to be made, either to stop nursing or to stop the medicine, taking into account how important the medicine is to the mother.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.